EU External Trade - PHARMACEUTICAL PRODUCTS, Medicaments (excluding goods of heading|3002, 3005|or 3006) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale

The main extra-EU suppliers of PHARMACEUTICAL PRODUCTS, Medicaments (excluding goods of heading|3002, 3005|or 3006) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale are 🇨🇭 Switzerland, 🇺🇸 United States, 🇬🇧 United Kingdom. 🇨🇭 Switzerland leads with 37.9% of total imports (€78.3B). The HHI concentration index stands at 2392, indicating a Moderate market.

The EU exports PHARMACEUTICAL PRODUCTS, Medicaments (excluding goods of heading|3002, 3005|or 3006) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale to 10 extra-EU markets, reflecting solid diversification. 🇺🇸 United States remains the largest client (24.9%, €171.8B), followed by 🇺🇸 United States, 🇨🇭 Switzerland, 🇬🇧 United Kingdom.

Within the EU, the leading importers of PHARMACEUTICAL PRODUCTS, Medicaments (excluding goods of heading|3002, 3005|or 3006) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale are 🇧🇪 Belgium, 🇩🇪 Germany, 🇸🇮 Slovenia. 🇧🇪 Belgium accounts for 18.8% of EU imports.

In 2025, imports were surging (16.6%) and exports rising (10.0%) compared to the previous year.